These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24581625)

  • 1. Stratified medicines: towards better treatment for disease.
    Bell J
    Lancet; 2014 Feb; 383 Suppl 1():S3-5. PubMed ID: 24581625
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicine: Eyes on the target.
    Eisenstein M
    Nature; 2015 Nov; 527(7578):S110-2. PubMed ID: 26580159
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 5. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 6. Target therapy in elderly breast cancer patients.
    Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 8. Personalised cancer management: closer, but not here yet.
    Piccart M
    Ann Oncol; 2013 Aug; 24(8):1951-5. PubMed ID: 23878113
    [No Abstract]   [Full Text] [Related]  

  • 9. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
    Ahmed S; Sami A; Xiang J
    Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual blockade of HER2 - twice as good or twice as toxic?
    Fralick M; Hilton JF; Bouganim N; Clemons M; Amir E
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):593-603. PubMed ID: 22748560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy of Breast Cancer.
    Janni W
    Oncol Res Treat; 2016; 39(3):100-1. PubMed ID: 27031668
    [No Abstract]   [Full Text] [Related]  

  • 13. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
    Lazaro G; Smith C; Goddard L; Jordan N; McClelland R; Barrett-Lee P; Nicholson RI; Hiscox S
    Endocr Relat Cancer; 2013 Oct; 20(5):691-704. PubMed ID: 23900794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report blames NICE for hastening decline of UK biotech.
    Moran N
    Nat Biotechnol; 2009 Mar; 27(3):215-7. PubMed ID: 19270658
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.
    Stutz E; Gautschi O; Fey MF; Gugger M; Tschan MP; Rothschild SI
    Future Oncol; 2014 Feb; 10(2):211-7. PubMed ID: 24490607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
    Albini A; Cesana E; Donatelli F; Cammarota R; Bucci EO; Baravelli M; Anzà C; Noonan DM
    Future Cardiol; 2011 Sep; 7(5):693-704. PubMed ID: 21929348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.